Open Collections

UBC Faculty Research and Publications

Drugs for Alzheimer’s Disease Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 56 examines drugs for Alzheimer's disease. Conclusions: Donepezil has not been demonstrated to improve outcomes of importance to patients and caregivers (e.g. institutionalization or disability). Rivastigmine and galantamine have not been studied for these outcomes. AChE-I cause gastrointestinal, muscular, and other adverse effects and likely increase serious adverse events. There is no evidence that stopping AChE-I treatment is harmful. In advanced AD, memantine has not been demonstrated to improve outcomes of importance to patients and caregivers.

Item Metadata

Title
Drugs for Alzheimer’s Disease
Alternate Title
Therapeutics Letter 56
Creator
Therapeutics Initiative (University of British Columbia)
Date Issued
2005-08
Description
Therapeutics Letter 56 examines drugs for Alzheimer's disease. Conclusions: Donepezil has not been demonstrated to improve outcomes of importance to patients and caregivers (e.g. institutionalization or disability). Rivastigmine and galantamine have not been studied for these outcomes. AChE-I cause gastrointestinal, muscular, and other adverse effects and likely increase serious adverse events. There is no evidence that stopping AChE-I treatment is harmful. In advanced AD, memantine has not been demonstrated to improve outcomes of importance to patients and caregivers.
Subject
Alzheimer Disease; Donezepil; Galantamine; Memantine; Rivastigmine
Genre
Other
Type
Text
Language
eng
Notes
The UBC TI is funded by the BC Ministry of Health to provide evidence-based information about drug therapy. We neither formulate nor adjudicate provincial drug policies.
Date Available
2023-06-20
Provider
Vancouver : University of British Columbia Library
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
DOI
10.14288/1.0433635
URI
http://hdl.handle.net/2429/85045
Affiliation
Medicine, Faculty of; Anesthesiology, Pharmacology and Therapeutics, Department of
Peer Review Status
Reviewed
Scholarly Level
Faculty; Researcher
Rights URI
http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International